<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">AMIFOSTINE</span><br/>(am-i-fos'teen)<br/><span class="topboxtradename">Ethyol<br/></span><b>Classifications:</b> <span class="classification">cytoprotective agent</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg vial</p>
<h1><a name="action">Actions</a></h1>
<p>Amifostine reduces cytotoxic damage induced by radiation or alkylating agents in well-oxygenated cells. Protective effects
         appear to be mediated by the formation of a thiol metabolite of amifostine (WR-1065), which removes free radicals from normal
         cells, and by promotion of the repair of macromolecules. The higher concentration of WR-1065, the metabolite, in normal tissues
         is available to bind to metabolites produced by cisplatin and also to remove free radicals that are generated in tissues exposed
         to cisplatin.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Amifostine is cytoprotective in the kidney, bone marrow, and GI mucosa, but not in the brain or spinal cord. The cytoprotection
         results in decreased myelosuppression and peripheral neuropathy.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Reduction of the cumulative renal toxicity associated with cisplatin.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Sensitivity to aminothiol compounds or mannitol, patients with potentially curable malignancies, hypotensive patients or those
         who are dehydrated, pregnancy (category C), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients at risk for hypocalcemia, cardiovascular disease (i.e., arrhythmias, CHF, TIA, CVA).</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Renal Protection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 910 mg/m<sup>2</sup> once daily<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Give antiemetics, adequately hydrate, and defer antihypertensives for 24 h prior to administration.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype"> IV Infusion:</span> Reconstitute IV solution by adding 9.5 mL of NS injection to a single-dose vial.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span> Infuse over no more than 15 min, beginning 30 min before chemotherapy; place patient in supine position prior to and during
                  infusion.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/Additive:</span> Do not mix with any solutions other than NS. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store reconstituted solution at 15°30° C (59°86° F) for 5 h or refrigerate up to 24 h.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span>
<span class="speceff-common">Transient reduction in blood pressure</span>. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting</span>. <span class="typehead">Other:</span> Infusion reactions (flushing, feeling of warmth or coldness, chills, dizziness, somnolence, hiccups, sneezing), hypocalcemia,
      hypersensitivity reactions. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span>  58 min. <span class="typehead">Metabolism:</span> Rapidly metabolized in liver to active free thiol metabolite. <span class="typehead">Elimination:</span> Renally excreted. <span class="typehead">Half-Life:</span> 8 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of hypocalcemia and fluid balance if vomiting is significant.</li>
<li>Monitor BP every 5 min during infusion. Stop infusion if systolic BP drops significantly from baseline (e.g., baseline[drop]:
            80[50]) and place patient flat with legs raised. Restart
            infusion if BP returns to normal in 5 min.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Know and understand adverse effects.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>